Artiva Biotherapeutics, Inc.

Contributing Author

Recent Articles by Artiva Biotherapeutics, Inc.

Oct-02	Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 ARTV GlobeNewswire
Oct-01	Artiva Biotherapeutics Highlights Updated AlloNK Data in Sjogren Disease Presented at the 17th International Symposium on Sjogren's Disease (ISSjD 2026) ARTV GlobeNewswire
Sep-23	Artiva Biotherapeutics Announces Oral Presentation of AlloNK Clinical Data at the 17th International Symposium on Sjogren's Disease ARTV GlobeNewswire
Sep-17	Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum ARTV GlobeNewswire
Sep-08	Artiva Biotherapeutics Provides Update on Planned AlloNK Data Disclosures and Development Milestones for the Remainder of 2026 ARTV GlobeNewswire
Sep-02	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September ARTV GlobeNewswire
Aug-06	Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights ARTV GlobeNewswire
Jul-17	Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ARTV +7.96% GlobeNewswire
Jun-23	Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference ARTV GlobeNewswire
Jun-08	Artiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today ARTV GlobeNewswire
May-28	Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference ARTV GlobeNewswire
May-19	Artiva Biotherapeutics Announces Multiple AlloNK Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases ARTV -7.27% ARTV -8.30% GlobeNewswire
May-19	Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development ARTV -7.27% GlobeNewswire
May-08	Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants ARTV -13.02% GlobeNewswire
May-08	Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights ARTV -13.02% GlobeNewswire
May-08	Artiva Announces Positive Initial Clinical Data with AlloNK Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 ARTV -13.02% GlobeNewswire
Apr-08	Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference ARTV -7.20% GlobeNewswire
Mar-10	Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights ARTV +6.48% ARTV +17.27% GlobeNewswire
Feb-25	Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference ARTV GlobeNewswire
Feb-24	Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant ARTV GlobeNewswire
Feb-19	Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors ARTV +9.16% GlobeNewswire
Jan-21	Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL ARTV GlobeNewswire
Nov-12	Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK in Autoimmune Disease ARTV +10.86% GlobeNewswire
Nov-12	Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights ARTV +10.86% GlobeNewswire
Nov-03	Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK ARTV -9.59% GlobeNewswire
Oct-30	Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November ARTV -10.25% ARTV +5.84% GlobeNewswire
Oct-16	Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update ARTV -7.97% ARTV +116.97% GlobeNewswire
Aug-25	Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025 ARTV GlobeNewswire
Aug-06	Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights ARTV -6.82% ARTV -8.01% GlobeNewswire
May-28	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference ARTV ARTV +6.77% GlobeNewswire
May-13	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting ARTV ARTV -11.71% GlobeNewswire
May-08	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights ARTV GlobeNewswire

Artiva Biotherapeutics, Inc.

Recent Articles by Artiva Biotherapeutics, Inc.

Upgrade your Finviz experience